Gapping down
In reaction to disappointing earnings/guidance: SSL -8.7%, FAST -0.5%, (reports May net sales)
Select EU financial related names showing weakness: LYG -1.9%, DB -1.4%, RBS -1%, HSBC -0.7%, BCS -0.5%
Other news: DNAI -57.2% (interim results from the Wolverine Phase 2 trial of PNT2258; will suspend development of PNT2258 pending further review), ADMP -41.5% (receives Complete Response Letter from FDA for its Epinephrine pre-filled syringe NDA), OCUL -40.9% (reports Phase 3 Clinical Trial of DEXTENZA - Primary endpoint for ocular itching not achieved), MRTX -28.6% (light volume, presented data at ASCO), ABBV -3.6% (following disappointing Rova-T data treating small cell lung cancer (SCLC) at ASCO), CDXC -2.8% (to offer ~1.1 mln shares of common stock at $4.70/share), OLLI -1.4% (affiliates of CCMP Capital Advisors intend to offer 10 mln shares of the co's common stock in an underwritten public offering), WPX -1.4% (announces a 45 mln share underwritten public offering of common stock)
Analyst comments: PWE -8.3% (downgraded to Underweight at JP Morgan ), CUDA -2.6% (downgraded to Mkt Underperform from Mkt Perform at JMP Securities), TSN -2.2% (downgraded to Market Perform from Outperform at BMO Capital), AWK -1.9% (downgraded to Neutral from Outperform at Boenning & Scattergood), RGR -1.4% (downgraded to Hold from Buy at BB&T Capital Mkts), PPC -0.7% (downgraded to Market Perform from Outperform at BMO Capital), QLIK -0.5% (downgraded to Neutral from Buy at SunTrust).